Raymond James upgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to an "Outperform" rating, raising the price target from $820 to$870.The company's Q4 2025 earnings call likely highlighted key financial metrics and strategic plans, supporting a positive future outlook.Despite a slight decrease in stock price to $741.45, Regeneron's market performance remains dynamic, with a significant market capitalization of approximately$76.58 billion.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biote ...